With the recent advent of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) shown to be associated with dramatic weight loss effects coupled with rapid increased use of these products among patients with obesity [38], we might anticipate an increase in obesity policy focused on healthcare beyond the database period. This evidence concerns the gene GLP1R and obesity disorder.